Are Every-Other-Month Injections of VEGF Trap-Eye (Aflibercept) as Effective as Monthly Injections of Lucentis in Treating Macular Degeneration?
December 1, 2010
Regeneron Pharmaceutical recently announced that two clinical trials had shown that its experimental drug, VEGF Trap-Eye (aflibercept ophthalmic solution), dosed every two months was as effective and safe as Lucentis (ranibizumab) injections given monthly in treating macular degeneration.
In the North American trial, 96 percent of patients receiving 2mg of VEGF Trap-Eye every two months achieved maintenance of vision compared to 94 percent of patients receiving Lucentis 0.5mg dosed every month. Similar results were seen in a second international trial conducted by partner Bayer in Europe, Asia and Latin America.
Regeneron stated that the results of the studies indicate that VEGF Trap-Eye could establish a new treatment paradigm for the management of patients with wet AMD by offering predictable every-other-month dosing instead of monthly injections. Less frequent injections would represent a greater convenience to patients.
Read the full press release from Regeneron here.
You might also enjoy...
- VEGF Trap-Eye Sees Positive Results in Phase 3 GALILEO Study in Patients with Macular Edema Due to CRVO
- Regeneron Commence Study of VEGF Trap-Eye for CVRO Treatment
- Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for Wet Age-Related Macular Degeneration
- Study Shows Fovista Administered in Combination With Lucentis Yields Better Results Treating Wet AMD Than Lucentis Alone
- Is VEGF Trap-Eye Effective in Treating Macular Edema?
Jump down to form below to submit your own comments